Tag Archives: FDA
Tirzepatide CV Approval: The Overlooked 0.92 Hazard Ratio
Tirzepatide gained an FDA cardiovascular indication on 28 August 2026, from a trial that met non-inferiority and missed superiority at P = 0.09.
No account yet?
Create an AccountJoin the list for batch updates and new compound announcements. We will send you a single-use 8% code once you confirm your address.
Every batch is tested separately
Purity is measured per production lot, not once per product.
See the batch records